Delving into the Latest Updates on Beijing Lean Taixiang Technology Development Co. Ltd. with Synapse

Overview

Tags

Neoplasms

Respiratory Diseases

Therapeutic vaccine

Genetically engineered subunit vaccine

Conjugated vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Therapeutic vaccine	1
Genetically engineered subunit vaccine	1
Conjugated vaccine	1

Top 5 Target	Count

EGFR(Epidermal growth factor receptor erbB1)	1

主要目的：评价JY03注射液在转移性晚期实体瘤患者中的安全性。次要目的：（1）评价JY03注射液在转移性晚期实体瘤患者中的其他安全性；（2）评价JY03注射液在转移性晚期实体瘤患者中的药代动力学特征（PK）；（3）评价JY03注射液在转移性晚期实体瘤患者中的免疫原性；（4）评价JY03注射液在转移性晚期实体瘤患者中的有效性。探索性目的：（1）评价LAG-3表达水平与有效性的关系；（2）评价JY03注射液治疗后T细胞的激活与有效性的关系。

[Translation]

Primary Objective: To evaluate the safety of JY03 injection in patients with metastatic advanced solid tumors. Secondary Objectives: (1) To evaluate other safety profiles of JY03 injection in patients with metastatic advanced solid tumors; (2) To evaluate the pharmacokinetic characteristics (PK) of JY03 injection in patients with metastatic advanced solid tumors; (3) To evaluate the immunogenicity of JY03 injection in patients with metastatic advanced solid tumors; (4) To evaluate the efficacy of JY03 injection in patients with metastatic advanced solid tumors. Exploratory Objectives: (1) To evaluate the relationship between LAG-3 expression levels and efficacy; (2) To evaluate the relationship between T cell activation and efficacy after treatment with JY03 injection.

Start Date12 Mar 2026

Sponsor / Collaborator

Beijing Oriental Biotech Co., Ltd.

[+1]

CTR20242318

/ RecruitingPhase 2

在晚期肝细胞癌（HCC）患者中评价重组抗VEGFR2全人源单克隆抗体（JY025）注射液的有效性和安全性的II期临床研究

[Translation] A phase II clinical study to evaluate the efficacy and safety of a recombinant anti-VEGFR2 fully human monoclonal antibody (JY025) injection in patients with advanced hepatocellular carcinoma (HCC)

评价JY025注射液（联合最佳支持治疗）治疗晚期肝细胞癌的有效性、安全性和免疫原性。

[Translation]

To evaluate the efficacy, safety, and immunogenicity of JY025 injection (combined with best supportive care) in the treatment of advanced hepatocellular carcinoma.

Start Date22 Aug 2024

Sponsor / Collaborator

Beijing Oriental Biotech Co., Ltd.

[+1]

CTR20221676

/ RecruitingPhase 2

重组人源化抗VEGF单克隆抗体（JY028）注射液治疗新生血管性（湿性）年龄相关性黄斑变性患者的有效性和安全性的多中心、随机、开放II期临床试验

[Translation] A multicenter, randomized, open-label phase II clinical trial of the efficacy and safety of recombinant humanized anti-VEGF monoclonal antibody (JY028) injection in the treatment of patients with neovascular (wet) age-related macular degeneration

评价JY028 注射液不同给药剂量的有效性、安全性、免疫原性和药代动力学特征。

[Translation]

To evaluate the efficacy, safety, immunogenicity and pharmacokinetic characteristics of JY028 injection at different dosages.

Start Date02 Sep 2022

Sponsor / Collaborator

Beijing Oriental Biotech Co., Ltd.

[+1]

100 Clinical Results associated with Beijing Lean Taixiang Technology Development Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Beijing Lean Taixiang Technology Development Co. Ltd.

Login to view more data

100 Deals associated with Beijing Lean Taixiang Technology Development Co. Ltd.

Login to view more data

100 Translational Medicine associated with Beijing Lean Taixiang Technology Development Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 06 Nov 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1

1

Login to view more data